AbCellera Biologics Inc.

ABCL Nasdaq SEC CIK 1703057
Follow AbCellera Biologics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $10.6M +18.8% vs same quarter last year
Net income −$40.8M +28.6% vs same quarter last year
EPS, diluted −$0.13 +31.6% vs same quarter last year
Operating cash flow $26.9M +151.2% vs same quarter last year
Revenue by quarter
$5.1M
$4.2M
$17.1M
$9M
$44.9M
$8.3M
$4.1M
$10.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$75.1M−$146.4M
FY24$28.8M−$162.9M
FY23$38M−$146.4M
FY22$485.4M$158.5M
FY21$375.2M$153.5M
FY20$233.2M$118.9M
FY19$11.6M−$2.2M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−289%−194.9%
FY24−1091.7%−564.8%
FY23−623.8%−385%
FY2244.6%32.7%
FY2154.5%40.9%
FY2066.9%51%
FY19−35.5%−19%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200M$300MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$174.1M
FY24−$187M
FY23−$120.8M
FY22$206.7M
FY21$186.1M
FY20$13M
FY19−$1.3M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • AbCellera Biologics
  • Healthcare median
−600%−400%−200%0%200%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearAbCellera BiologicsHealthcare median
FY25−194.9%−30.6%
FY24−564.8%−47%
FY23−385%−58%
FY2232.7%−80.4%
FY2140.9%−71.9%
FY2051%−62.2%
FY19−19%−46.3%
FY18-−49.6%